GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Cardiome Pharma Corporation (CRME) [hlAlert]

Rating:
Outperform
CRME
down 53.87 %

Cardiome Pharma Corporation (CRME) rated Outperform with price target $6 by Leerink Swann

Posted on: Thursday,  Mar 19, 2009  8:25 AM ET by Leerink Swann

Leerink Swann rated Outperform Cardiome Pharma Corporation (NASDAQ: CRME) on 03/19/2009. Previously Leerink Swann rated Outperform Cardiome Pharma Corporation (NASDAQ: CRME)
on 11/17/2008., when the stock price was $19.10. Since then, Cardiome Pharma Corporation has lost 53.87% as of 08/27/2015's recent price of $8.81.
If you would have followed the previous Leerink Swann 's recommendation on CRME, you would have lost 53.87% of your investment in 2474 days.

Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with two clinical drug programs focused on atrial arrhythmia (intravenous and oral dosing), and a pre-clinical program directed at improving cardiovascular function.

Leerink Swann Equity Research provides unique perspectives and agenda-setting healthcare recommendations for investors. Supported by industry-based intelligence and thorough market examination, our proprietary research enables our clients to make well-informed healthcare investment decisions. Our investment perspectives are driven by proprietary insights from MEDACorp. MEDACorp's more than 25,000 network professionals work with new and/or development-stage pharmaceuticals, medical devices and biotherapeutics on a daily basis. MEDACorp's extensive knowledge of products and research enables Leerink Swann to provide growth-focused clients an expertise earned through experience.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/19/2009 8:25 AM Buy
None
14.10 30.00
as of 12/31/2009
1 Week up  43.64 %
1 Month up  62.93 %
3 Months up  51.27 %
1 YTD up  43.95 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/17/2008 1:25 PM Buy
None
19.10 40.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy